European Commission – Antitrust: Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine

· 1 min read · European Commission

European Commission Press release Brussels, 9 July 2014 The European Commission has imposed fines totalling €427.7 million on the French pharmaceutical company Servier and five producers of generic medicines – namely, Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin – for concluding a series of deals of deals… …read more Source: European Commission Competition Press Releases

Cite this post

OSCOLA

21st Century Competition, 'European Commission – Antitrust: Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine' (21st Century Competition, 9 July 2014) <https://www.twentyfirstcenturycompetition.com/2014/07/european-commission-antitrust-commission-fines-servier-and-five-generic-companies-for-curbing-entry-of-cheaper-versions-of-cardiovascular-medicine/> accessed 26 March 2026.

Chicago

21st Century Competition. "European Commission – Antitrust: Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine." 21st Century Competition, 9 July 2014. https://www.twentyfirstcenturycompetition.com/2014/07/european-commission-antitrust-commission-fines-servier-and-five-generic-companies-for-curbing-entry-of-cheaper-versions-of-cardiovascular-medicine/.

BibTeX

@misc{21st-century-competition2014, author = {21st Century Competition}, title = {{European Commission – Antitrust: Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine}}, year = {2014}, url = {https://www.twentyfirstcenturycompetition.com/2014/07/european-commission-antitrust-commission-fines-servier-and-five-generic-companies-for-curbing-entry-of-cheaper-versions-of-cardiovascular-medicine/}, note = {21st Century Competition} }
Download .bib file

Related Posts